190 related articles for article (PubMed ID: 3170992)
21. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
[TBL] [Abstract][Full Text] [Related]
22. Local intranasal immunotherapy for grass-allergic rhinitis.
Georgitis JW; Reisman RE; Clayton WF; Mueller UR; Wypych JI; Arbesman CE
J Allergy Clin Immunol; 1983 Jan; 71(1 Pt 1):71-6. PubMed ID: 6337198
[TBL] [Abstract][Full Text] [Related]
23. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
[TBL] [Abstract][Full Text] [Related]
24. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass.
Nelson HS; Oppenheimer J; Buchmeier A; Kordash TR; Freshwater LL
J Allergy Clin Immunol; 1996 Jun; 97(6):1193-201. PubMed ID: 8648012
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
26. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis.
Clavel R; Bousquet J; André C
Allergy; 1998 May; 53(5):493-8. PubMed ID: 9636808
[TBL] [Abstract][Full Text] [Related]
28. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass.
Bozek A; Kolodziejczyk K; Krajewska-Wojtys A; Jarzab J
Ann Allergy Asthma Immunol; 2016 Feb; 116(2):156-61. PubMed ID: 26815709
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study.
Tari MG; Mancino M; Ghezzi E; Frank E; Cromwell O
Allergy; 1997 Jan; 52(1):65-74. PubMed ID: 9062631
[TBL] [Abstract][Full Text] [Related]
30. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis.
Bertoni M; Cosmi F; Bianchi I; Di Berardino L
Ann Allergy Asthma Immunol; 1999 Jan; 82(1):47-51. PubMed ID: 9988206
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever.
Ortolani C; Pastorello EA; Incorvaia C; Ispano M; Farioli L; Zara C; Pravettoni V; Zanussi C
Allergy; 1994 Jan; 49(1):13-21. PubMed ID: 8198235
[TBL] [Abstract][Full Text] [Related]
33. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
35. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study.
Andri L; Senna G; Betteli C; Givanni S; Andri G; Dimitri G; Falagiani P; Mezzelani P
J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):34-41. PubMed ID: 8568135
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
37. The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis.
Jerzynska J; Stelmach W; Rychlik B; Lechańska J; Podlecka D; Stelmach I
Allergy Asthma Proc; 2016; 37(2):105-14. PubMed ID: 26932169
[TBL] [Abstract][Full Text] [Related]
38. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
39. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
[TBL] [Abstract][Full Text] [Related]
40. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
